Abstract
Human B cell stimulatory factor 2 (BSF-2) was originally charac-terized and isolated as a T cell-derived factor that caused the terminal maturation of activated B cells to immunoglobulin-producing cells1,2. Molecular cloning of the complementary DNA predicts that BSF-2 is a protein of relative molecular mass (Mr) 26,000 similar or identical to interferon β2, hybridoma plasmacytoma growth factor and hepatocyte stimulating factor3–7. IL-6 has been proposed as a name for this molecule8,9. It is now known that BSF-2 has a wide variety of biological functions and that its target cells are not restricted to normal B cells1,10. Responses are also seen in T cells11,12, plasmacytomas6, hepatocytes7,13, haematopoietic stem cells14, fibroblasts15 and rat phoeochromocytoma, PC 12 (Satoh, T. et al., manuscript in preparation). Of particular interest to this report is that human BSF-2 is a potent growth factor for murine plasmacytomas and hybridomas6,8,10. This observation suggested to us that constitutive expression of BSF-2 or its receptor could be responsible for the generation of human myelomas. In this study we report that myeloma cells freshly isolated from patients produce BSF-2 and express its receptors. Moreover, anti-BSF-2 antibody inhibits the in vitro growth of myeloma cells. This is direct evidence that an autocrine loop is operating in oncogenesis of human myelomas.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hirano, T. et al. Proc. natn. Acad. Sci. U.S.A. 82, 5490–5494 (1985).
Hirano, T. et al. Proc. natn. Acad. Sci. U.S.A. 84, 228–231 (1987).
Hirano, T. et al. Nature 324, 73–76 (1986).
Haegeman, G., Content, J., Volckaert, G., Derynck, R., Tavernier, J. & Fiers, W. Eur. J. Biochem. 159, 625–632 (1986).
Zilberstein, A., Ruggieri, R., Korn, J. H. & Revel, M. EMBO J. 5, 2529–2537 (1986).
Van Damme, J. et al. J. exp. Med. 165, 914–919 (1987).
Andus, T. et al.1 FEBS Lett. 221, 18–22 (1987).
Poupart, P. et al. EMBO J. 6, 1219–1224 (1987).
Yasukawa, K. et al. EMBO J. 6, 2939–2945 (1987).
Muraguchi, A. et al. J. exp. Med. (in the press).
Garman, R. D., Jacobs, K. A., Clark, S. C. & Raulet, D. H. Proc. natn. Acad. Sci. U.S.A. 84, 7629–7633 (1987).
Lotz, M. et al. J. exp. Med. (in the press).
Gauldie, J., Richards, C., Harnish, D., Lansdorp, P. & Baumann, H. Proc. natn. Acad. Sci. U.S.A. 84, 7251–7255 (1987).
Ikebuchi, K., Wong, G. G., Clark, S. C., Ihle, J. N., Hirai, Y. & Ogawa, M. Proc. natn. Acad. Sci. U.S.A. (in the press).
Kohase, M., Henriksen-DeStefano, D., May, L. T., Vilcek, J. & Sehgal, P. B. Cell 45, 659–666 (1986).
Durie, B. G. & Salmon, S. E. Cancer 36, 842–854 (1975).
Kawano, M., Fujimura, K., Iwato, K., Asaoku, H., Tanabe, O. & Kuramoto, A. Acta Haemat. jap. 49, 1740–1748 (1986).
Taga, T., Kawanishi, K., Hardy, R. R., Hirano, T. & Kishimoto, T. J. exp. Med. 166, 967–981 (1987).
Potter, M. & Boyce, C. Nature 193, 1086–1087 (1962).
Nordan, R. P. & Potter, M. Science 233, 566–569 (1986).
Sporn, M. B. & Todaro, G. J. New Engl. J. Med. 303, 878–880 (1980).
Sprm, M. B. & Roberts, A. B. Nature 313, 745–747 (1985).
Huang, J. S., Huang, S. S. & Deuel, T. F. Cell 39, 79–87 (1984).
Cuttitta, F. et al. Nature 316, 823–826 (1986).
Hirano, T., Matsuda, T., Hosoi, K., Okano, A., Matsui, H. & Kishimoto, T. Immun. Lett. 17, 41–45 (1988).
Chirwin, J. M., Przybla, A. E., MacDonald, R. L. & Rutter, W. J. Biochemistry 18, 5294–5299 (1979).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kawano, M., Hirano, T., Matsuda, T. et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332, 83–85 (1988). https://doi.org/10.1038/332083a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/332083a0
This article is cited by
-
Circulating biosignatures in multiple myeloma and their role in multidrug resistance
Molecular Cancer (2023)
-
The effect of non-surgical periodontal therapy on salivary IL-6 levels in patients with moderate to severe generalized chronic periodontitis
Irish Journal of Medical Science (1971 -) (2023)
-
Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients
Journal of Thrombosis and Thrombolysis (2022)
-
Socioeconomic inequalities in treatment and relative survival among patients with diffuse large B-cell lymphoma: a Hong Kong population-based study
Scientific Reports (2021)
-
IL-6 Directed Therapy in Transplantation
Current Transplantation Reports (2021)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.